Worth reading
75Important
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
13.8
Operating margin (year-on-year, %)Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials for financial resultsFirst quarter of the fiscal year ending December 202614 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales992 Hundreds of millions of yen+5.3%
Operating profit62.9 Hundreds of millions of yen+11.6%
Ordinary income¥73.9 100 million +16.9%pre-tax quarterly profit, IFRS
Net income¥42 100 million +4.5%profit for the quarter attributable to owners of the parent
Operating profit margin6.3 %
Selling, general and administrative expenses397.6 Hundreds of millions of yen
Results for the three months of the current quarterThe presentation includes standalone January–March results, including revenue of ¥99.20 billion, operating profit of ¥6.29 billion and profit for the quarter attributable to owners of the parent of ¥4.20 billion.
Full-year earnings forecast
Net Sales
4,300 Hundreds of millions of yen
Business profit
350 Hundreds of millions of yen
Operating profit
400 Hundreds of millions of yen
Profit for the period attributable to owners of the parent
250 Hundreds of millions of yen
EBITDA
550 Hundreds of millions of yen
EBITDA margin
12.8 %
ROIC
7 %
ROE
7.7 %
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。not disclosed (progress against the first-half guidance: revenue 47.2%, business profit 43.0%)
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Overall consolidated progress is broadly in line with the plan. General consumer products are broadly in line.Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Change in net sales+¥2.2 billion
Change in segment mix+¥1.1 billion
Decrease in gross profit from brand transfers-¥0.4 billion
Gross profit factors+¥3.7 billion (including +¥1.4 billion from exchange-rate movements)
Higher personnel expenses-¥1.0 billion
Increase in depreciation and amortization-¥0.4 billion
Higher other expenses-¥800 million in higher other expenses, among others
Selling, general and administrative expense factor-¥3.0 billion from SG&A expenses (including -¥1.1 billion from exchange-rate movements)
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Dubai crude oil70$/BBL
Domestic naphtha¥66,000/KL
Crude palm oil4,400RM/t
US dollars¥155
Thai baht¥4.7
New initiatives
- Transition to a business-unit structure
- Consolidation of Australia's PNB
- Launch of the oral healthcare business in Vietnam
- Launch and renewal of high-value-added products
- Transition to a proactive supply chain management model
- Planned transfer of shares in 2 chemical products subsidiaries
Key KPIsA metric the company considers important as a management benchmark.
- EBITDA110.1 Hundreds of millions of yen+13.5%
- EBITDA margin11.1 %yoy_change_pp0.8
- Year-on-year change in overseas personal care revenue8.8 %
- Oral healthcare revenue growth rate9.8 %
- Year-on-year growth on emerging overseas e-commerce platforms194 %
Unit price and quantity metricsThese figures show sales broken down by price and volume.
Japanese household products market
Sales value107 Year on year %
Unit sales101 Year on year %
Average price105 Year on year %
OTC pharmaceutical market
Sales value101 Year on year %
Unit sales99 Year on year %
Average price102 Year on year %
Segment results
General consumer products
Net Sales
573.7 Hundreds of millions of yen+3.6%
External revenue
481.7 Hundreds of millions of yen+2.3%
Business profit
40.6 Hundreds of millions of yen-8.1%
Industrial products
Net Sales
132.3 Hundreds of millions of yen-6.5%
External revenue
88 Hundreds of millions of yen-2.4%
Business profit
6.5 Hundreds of millions of yen-0.2%
Overseas expansion
Net Sales
469.8 Hundreds of millions of yen+10.7%
External revenue
419.6 Hundreds of millions of yen+11.1%
Business profit
28.9 Hundreds of millions of yen+60.7%
Other
Net Sales
13.8 Hundreds of millions of yen-49.8%
Business profit
-0.4 Hundreds of millions of yen
Consolidated total
Net Sales
992 Hundreds of millions of yen+5.3%
Business profit
60.1 Hundreds of millions of yen+13.8%
Medium-term management plan targets
Oral healthcare revenue growth rateCAGR of approximately 8% by 2027
Overseas revenue growth rateCAGR of approximately 10% by 2027
Overseas EBITDA marginApproximately +2 percentage points by 2027
General consumer products EBITDA marginApproximately +3–5 percentage points by 2027
Financial targets
ROIC
7 %
ROE
7.7 %
Market Size / Share
The presentation includes year-on-year changes in point-of-sale sales value for major categories in Japan and overseas. Sukin is No. 1 in Australia's natural beauty care brand market.Capital expenditures
¥142 100 million planned for 2026
Annual Dividend
Annual
¥34 per share
Interim
¥17 per share
End of period
¥17 per share
Payout ratio
37.6 %
Acquisition of treasury shares
Flexible repurchases and cancellation of treasury shares| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | First quarter of the fiscal year ending December 2026 |
| Net Sales | 992 Hundreds of millions of yen (YoY +5.3%) |
| Operating profit | 62.9 Hundreds of millions of yen (YoY +11.6%) |
| Ordinary income | ¥73.9 100 million (pre-tax quarterly profit, IFRS) (YoY +16.9%) |
| Net income | ¥42 100 million (profit for the quarter attributable to owners of the parent) (YoY +4.5%) |
| Operating profit margin | 6.3 % |
| Selling, general and administrative expenses | 397.6 Hundreds of millions of yen |
| Results for the three months of the current quarter | The presentation includes standalone January–March results, including revenue of ¥99.20 billion, operating profit of ¥6.29 billion and profit for the quarter attributable to owners of the parent of ¥4.20 billion. |
| Full-year earnings forecast | Net Sales 4,300 Hundreds of millions of yen / Business profit 350 Hundreds of millions of yen / Operating profit 400 Hundreds of millions of yen / Profit for the period attributable to owners of the parent 250 Hundreds of millions of yen / EBITDA 550 Hundreds of millions of yen / EBITDA margin 12.8 % / ROIC 7 % / ROE 7.7 % |
| Progress against full-year forecast | not disclosed (progress against the first-half guidance: revenue 47.2%, business profit 43.0%) |
| Self-assessment against the plan | Overall consolidated progress is broadly in line with the plan. General consumer products are broadly in line. |
| Segment results | General consumer products Net Sales 573.7 Hundreds of millions of yen (YoY +3.6%) / External revenue 481.7 Hundreds of millions of yen (YoY +2.3%) / Business profit 40.6 Hundreds of millions of yen (YoY -8.1%) / Industrial products Net Sales 132.3 Hundreds of millions of yen (YoY -6.5%) / External revenue 88 Hundreds of millions of yen (YoY -2.4%) / Business profit 6.5 Hundreds of millions of yen (YoY -0.2%) / Overseas expansion Net Sales 469.8 Hundreds of millions of yen (YoY +10.7%) / External revenue 419.6 Hundreds of millions of yen (YoY +11.1%) / Business profit 28.9 Hundreds of millions of yen (YoY +60.7%) / Other Net Sales 13.8 Hundreds of millions of yen (YoY -49.8%) / Business profit -0.4 Hundreds of millions of yen / Consolidated total Net Sales 992 Hundreds of millions of yen (YoY +5.3%) / Business profit 60.1 Hundreds of millions of yen (YoY +13.8%) |
| Breakdown of Factors Affecting the Change | Change in net sales +¥2.2 billion / Change in segment mix +¥1.1 billion / Decrease in gross profit from brand transfers -¥0.4 billion / Gross profit factors +¥3.7 billion (including +¥1.4 billion from exchange-rate movements) / Higher personnel expenses -¥1.0 billion / Increase in depreciation and amortization -¥0.4 billion / Higher other expenses -¥800 million in higher other expenses, among others / Selling, general and administrative expense factor -¥3.0 billion from SG&A expenses (including -¥1.1 billion from exchange-rate movements) |
| Key KPIs | 110.1 Hundreds of millions of yen (YoY +13.5%), 11.1 %, 8.8 %, 9.8 %, 194 % |
| Unit price and quantity metrics | Japanese household products market Sales value 107 Year on year (%) / Unit sales 101 Year on year (%) / Average price 105 Year on year (%) / OTC pharmaceutical market Sales value 101 Year on year (%) / Unit sales 99 Year on year (%) / Average price 102 Year on year (%) |
| Assumptions Underlying the Business Outlook | Dubai crude oil 70$/BBL / Domestic naphtha ¥66,000/KL / Crude palm oil 4,400RM/t / US dollars ¥155 / Thai baht ¥4.7 |
| Medium-term management plan targets | Oral healthcare revenue growth rate CAGR of approximately 8% by 2027 / Overseas revenue growth rate CAGR of approximately 10% by 2027 / Overseas EBITDA margin Approximately +2 percentage points by 2027 / General consumer products EBITDA margin Approximately +3–5 percentage points by 2027 |
| Financial targets | ROIC 7 % / ROE 7.7 % |
| Annual Dividend | Annual ¥34 per share / Interim ¥17 per share / End of period ¥17 per share |
| Payout ratio | 37.6 % |
| Acquisition of treasury shares | Flexible repurchases and cancellation of treasury shares |
| Capital expenditures | ¥142 100 million (planned for 2026) |
| Market Size / Share | The presentation includes year-on-year changes in point-of-sale sales value for major categories in Japan and overseas. Sukin is No. 1 in Australia's natural beauty care brand market. |
| New initiatives | Transition to a business-unit structure, Consolidation of Australia's PNB, Launch of the oral healthcare business in Vietnam, Launch and renewal of high-value-added products, Transition to a proactive supply chain management model, Planned transfer of shares in 2 chemical products subsidiaries |
Items this document does not state (6)
Gross Profit MarginNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Higher value-added oral healthcare products and services progressed in Japan and overseas, the newly consolidated companies in Vietnam and Australia contributed, and changes in the business portfolio mix contributed to higher gross profit. In Japan, selling, general and administrative expenses increased as the Company made proactive investments in advertising and promotion, mainly in oral healthcare.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.